{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:04:38Z","timestamp":1784988278549,"version":"3.55.0"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["Award number P30 CA016672"],"award-info":[{"award-number":["Award number P30 CA016672"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Diabetes Sci Technol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Continuous glucose monitoring (CGM) is increasingly used in patients with cancer, a population in whom HbA1c may be unreliable. The Glycemia Risk Index (GRI) is a CGM-derived measure integrating hypoglycemia and hyperglycemia risk. We evaluated trends in GRI and other CGM metrics among adults followed in a remote CGM (RCGM) clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective chart review of adults (\u226518 years) with diabetes and cancer seen at a comprehensive cancer center in 2024. Eligible patients had \u22652 CGM assessments (\u22651 RCGM) and a baseline glucose management indicator (GMI) or HbA1c \u22658.0%. Generalized linear mixed models examined the effects of visit sequence (time) and RCGM use on GRI, GMI, average glucose, time in range (TIR), time above range (TAR), and time below range (TBR). Pre-specified conservative and liberal noninferiority margins were applied to the remote-use effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-two patients (mean age 60.2 \u00b1 10.6 years; 95% type 2 diabetes) were included. At baseline, mean GRI was 70 \u00b1 27, GMI 8.5% \u00b1 1.1%, average glucose 214 \u00b1 46 mg\/dL, TIR 38% \u00b1 21%, TAR 61% \u00b1 21%, and TBR 1% \u00b1 1%. Across sequential assessments, GRI, GMI, average glucose, and TAR decreased, whereas TIR increased (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.05). Remote CGM did not predict any glycemic outcome. Under liberal margins, RCGM was noninferior to nonremote review for GRI, GMI, TIR, and TAR, and noninferior for TBR under both conservative and liberal margins.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Sequential CGM review was associated with improved glycemic quality in adults with diabetes and cancer. Remote CGM achieved glycemic outcomes comparable with nonremote review, supporting its use as a viable adjunct to in-person visits in the oncology setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/19322968261470745","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:01:25Z","timestamp":1784822485000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in Glycemia Risk Index Over Time in Patients With Diabetes and Cancer Undergoing Remote Continuous Glucose Monitoring"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-7249","authenticated-orcid":false,"given":"Deborah A.","family":"Osafehinti","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-3572","authenticated-orcid":false,"given":"Sonali","family":"Thosani","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-0202","authenticated-orcid":false,"given":"Steven P.","family":"Weitzman","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1684"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071808"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz078"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S007"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf211"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221085273"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12496-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-019-00482-3"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03480-9"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-023-02032-z"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2025.0232"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07745-z"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1464071"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225735"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.4.468"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-013-2595-x"},{"key":"e_1_3_3_18_2","unstructured":"Gounden V Anastasopoulou C Zubair M. Clinical utility of fructosamine and glycated albumin. In: Jialal I ed. StatPearls [Internet]. StatPearls Publishing; 2026. Updated 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470185\/"}],"container-title":["Journal of Diabetes Science and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19322968261470745","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19322968261470745","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19322968261470745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:53:42Z","timestamp":1784987622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19322968261470745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":17,"alternative-id":["10.1177\/19322968261470745"],"URL":"https:\/\/doi.org\/10.1177\/19322968261470745","relation":{},"ISSN":["1932-2968","1932-2968"],"issn-type":[{"value":"1932-2968","type":"print"},{"value":"1932-2968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"19322968261470745"}}